United States birth rate rises from last year but is still lower than pre-pandemic; a drug plant closure in California could affect availability of 5 essential medications; the No Surprises Act prevented 2 million potential surprise bills in first 2 months of 2022, report says.
According to The Associated Press, there was a 1% increase in births in 2021, from 3.6 million in 2020 to 3.7 million 2021. However, even with this increase, US births were still approximately 86,000 births less than in 2019. Officials believe that the increase in births last year was a result of pregnancies put off due to the uncertainty of the pandemic, with an increase in births coming from older moms in particular. The United States has seen a decline in birth rates for more than a decade.
The recent closure of a plant in Irvine, California, from Teva Pharmaceuticals could spell trouble for 24 generic sterile injectable drugs and 5 essential medications that the company has a 15% share of. The plant was closed due to warning letters from the FDA about contamination, dirty changing rooms and scrubs, and a lack of sterilization and testing of equipment. The injectable drugs that are most vulnerable to a shortage are vasodilator alprostadil, amikacin, bleomycin, dacarbazine, idarubicin, ifosfamide, mitoxantrone, streptozocin, topotecan, and octreotide. The report from the End Drug Shortages Alliance listed suppliers that could increase production.
According to a report from AHIP and Blue Cross Blue Shield Association, the No Surprises Act prevented more than 2 million surprise medical bills in commercially insured patients in the first 2 months of 2022. Should the trend hold, more than 12 million surprise bills will be avoided in 2022. The No Surprises Act established a process for resolving disagreements on what health plans will pay an out-of-network provider or facility, which has brought up the question of how many claims could be disputed each year and whether that will affect affordability of health care.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More